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Albumin has been widely used in patients with cirrhosis in an attempt to improve circulatory and renal functions. The 
benefits of albumin infusions in preventing the deterioration in renal function associated with large-volume paracentesis, 
spontaneous bacterial peritonitis, and established hepatorenal syndrome in conjunction with a vasoconstrictor are well 
established. While some of these indications are supported by the results of randomized studies, others are based 
only on clinical experience and have not been proved in prospective studies. The paucity of well-designed trials, the 
high cost of albumin, the lack of a clear-cut survival benefit, and fear of transmitting unknown infections make the use 
of albumin controversial. The recent development of the molecular adsorbent recirculating system, an albumin dialysis, 
is an example of the capacity of albumin to act by mechanisms other than its oncotic effect. Efforts should be made to 
define the indications for albumin use, the dose required, and predictors of response, so that patients gain the maximum 
benefit from its administration.
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INTRODUCTION
Albumin is an effective plasma volume expander due 
to its high oncotic activity and prolonged half-life in the 
intravascular compartment. Considering these factors, 
it is not surprising that albumin has been used for many 
years in the management of patients with cirrhosis and 
ascites [1]. Evidence has been presented in support of albu-
min use in the management of complications of cirrhosis, 
but arguments against such use have also been put forth, 
especially because albumin infusions are costly and this 
treatment has not been demonstrated to improve survival 
[2]. The debate has been fostered by the results of a recent 
meta-analysis showing that albumin administration may 
increase mortality in critically ill patients [3].
The main physiologic function of albumin is to main-
tain colloid osmotic pressure, but in the past few years 
many other functions have been recognized. These include 
ligand binding and transport of various molecules, in ad-
dition to antioxidant and anti-inflammatory actions [4]. 
These functions of albumin could be applied to various 
clinical situations, including septic shock. Patients with 
cirrhosis, especially those in the advanced decompensated 
stage, exhibit effective arterial hypovolemia and are prone 
to the development of sepsis. Thus, the possible indica-
tions for albumin use in these cirrhotic patients are rapidly 
expanding. This review discusses the physiologic actions 
of albumin and the potential benefits and pitfalls of albu-
min use in patients with end-stage liver disease.14    The Korean Journal of Internal Medicine Vol. 27, No. 1, march 2012
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phySIOLOgIC fUNCTIONS Of ALbUMIN
Colloidal osmotic pressure
Albumin is predominantly an extravascular protein, 
and its serum concentration is —40 g/L, suggesting a total 
intravascular mass of —120 g [5]. The interstitial con-
centration is lower (14 g/L) and varies among anatomic 
regions. However, the total extravascular mass is —160 g 
[5]. Some is easily mobilized from loose interstitial tissues, 
whereas the remainder is tightly bound. Albumin appears 
to circulate from the intravascular to extravascular spaces, 
and the transcapillary escape rate is determined by the 
capillary and interstitial free albumin concentrations, 
microvascular permeability to albumin, movement of sol-
vents and solutes, and transcapillary electrical charge. In 
patients with hypoalbuminemia (especially when associ-
ated with inflammation or sepsis), whose capillaries are 
known to be hyper-permeable, leakage of albumin into the 
interstitial space draws water and produces edema [6].
Transport
Albumin has a strong negative charge, but binds weakly 
and reversibly to both cations and anions. Therefore, it 
functions as a transport molecule for a large number of 
metabolites, including fatty acids, ions, thyroxine, biliru-
bin, and amino acids (Table 1). Albumin also binds cova-
lently and irreversibly with d-glucose and d-galactose. The 
glycosylation of albumin, which is to a certain extent age-
dependent, affects its charge and, therefore, may influence 
capillary permeability characteristics [5].
Antioxidant effects
Albumin is the major extracellular source of thiols. 
These sulphydryl groups are scavengers of reactive oxygen 
and nitrogen species. Albumin can also limit the produc-
tion of reactive oxidative species by binding free copper, 
an ion known to be particularly important in accelerating 
the production of free radicals. In sepsis, the administra-
tion of human albumin led to significantly increased levels 
of total plasma thiol levels. Unlike albumin concentra-
tions, however, which fell significantly between 5 minutes 
and 4 hours following administration, thiol remained 
significantly elevated for up to 18 hours following albumin 
administration [7]. These results suggest that the increase 
in plasma protein thiols associated with albumin admin-
istration is sustained long-term compared with plasma 
albumin levels, which is indicative of a beneficial albumin-
mediated thiol exchange in the plasma of these septic pa-
tients. Also, albumin may in this way influence redox bal-
ance, which has several important implications for other 
indices of critical illness, including capillary permeability, 
cell signaling processes, and drug metabolism and trans-
port [4].
Endothelial stabilization
Albumin’s ability to reduce injury to the endothelium 
caused by reactive oxygen and nitrogen species means 
that it may stabilize the endothelium and help to maintain 
capillary permeability. Albumin also interferes with neu-
trophil adhesion to the capillary endothelium [8], thereby 
reducing inflammation and aiding the maintenance of en-
dothelial integrity.
pharmacologic interactions and drug binding
Drugs with which albumin interacts are clinically sig-
nificant owing to their highly protein-bound state and low 
margins of safety, and include warfarin, phenytoin, non-
steroidal anti-inflammatory drugs, digoxin, midazolam, 
thiopental, and several antibiotics. The distribution vol-
ume of drugs bound to albumin may increase in hypoal-
buminemia, reducing their efficacy [5]. Administration 
of mixtures of loop diuretics with albumin has therefore 
been advocated, although this has been shown to be inef-
fective in cirrhotic patients with ascites.
Table 1. Albumin acts as a  transport vehicle and binds 
with drugs [5]
Transport vehicle for
Cholesterol
Bile pigments
Nitric oxide
Fatty acids
metals
Interacts with
Phenytoin
Non-steroidal anti-inflammatory drugs 
Digoxin
midazolam
Thiopental
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pAThOgENESIS Of ASCITES AND RENAL 
DySfUNCTION IN CIRRhOSIS
Evidence strongly indicates that renal dysfunction and 
ascites formation in cirrhosis are the final consequences of 
circulatory dysfunction. This is characterized by marked 
splanchnic arterial vasodilatation, causing a reduction in 
effective arterial blood volume and the homeostatic activa-
tion of vasoconstrictor and anti-natriuretic mechanisms. 
The exact mechanism(s) leading to this vasodilatation are 
incompletely understood, but may involve increased syn-
thesis/activity of vasodilator factors, including nitric oxide 
and vasodilator peptides [9,10]. These splanchnic arterial 
vasodilatations are likely responsible not only for the re-
duction in total systemic vascular resistance, but also for 
an abnormal distribution of blood volume with reduction 
of effective arterial blood volume (Fig. 1). Reduction of ef-
fective arterial volume stimulates the renin-angiotensin 
system and induces vasopressin release, which leads to 
continuous renal sodium and water retention, and ascites 
formation [11]. In contrast, no evidence supports a role for 
reduced vascular oncotic pressure due to hypoalbumin-
emia in the pathogenesis of ascites. Renal dysfunction in 
cirrhosis is of great clinical importance because its inten-
sity correlates with prognosis [1].
ALbUMIN USE IN gENERAL CLINICAL 
pRACTICE
Albumin has been used in many clinical scenarios, espe-
cially those requiring the improvement of colloid osmotic 
pressure (e.g., shock and sepsis) [12]. However, since the 
Cochrane Review reported that albumin administration 
to critically ill patients might increase the risk of death [3], 
the use of albumin in clinical practice, especially in the 
critical-care setting, has been controversial [13]. In addi-
tion, a large clinical trial that included 7,000 critically ill 
patients showed that normal saline was as effective as 4% 
albumin as a resuscitation fluid; no difference in morbid-
ity, length of stay in the critical-care unit or hospital, or 
survival was found [14,15]. With the added concerns of po-
tential transmission of known and unknown infections via 
administration of human albumin [16] and its high cost, 
the use of albumin in general clinical practice remains 
controversial [6].
ALbUMIN USE IN LIvER CIRRhOSIS
for the management of cirrhotic ascites
The standard treatment for cirrhotic ascites is sodium 
restriction and diuretic therapy. One randomized, con-
trolled trial assessed the effects of albumin plus standard 
diuretic therapy in cirrhotic patients with ascites; weekly 
infusions of 25 g albumin produced a significantly bet-
ter diuretic response, shorter hospital stays, and a lower 
likelihood of readmission to hospital than treatment with 
standard therapy [17]. Suppression of the activity of anti-
natriuretic systems, particularly the renin-angiotensin-
aldosterone system, probably accounts for an increase in 
the natriuretic response to diuretics with repeated albu-
min infusions [18]. Survival, however, was not affected by 
the addition of albumin [6]. Moreover, compared with the 
simple performance of paracentesis in a day-care unit, the 
logistic problems of intravenous albumin administration 
on a weekly basis, and its lack of cost-effectiveness, render 
this indication unjust and impractical in clinical practice 
[19]. Infusions of albumin plus diuretic therapy, therefore, 
cannot be recommended as the standard of care for these 
patients [6].
Increase in splanchnic
arterial vasodilation Decrease in cardiac output
Sodium retention and ascites
Type-2
hepatorenal
syndrome
Extreme
 
Progression of liver failure
and portal hypertension
Reduction in effective
arterial blood volume
Figure 1. Pathophysiology of ascites and circulatory dysfunction 
in portal hypertension. The initial event is splanchnic arterial 
vasodilation, which causes effective hypovolemia. When 
circulatory dysfunction is moderate, patients develop sodium 
retention. When it is severe, patients develop a profound 
impairment in free water excretion and dilutional hyponatremia 
[10].16    The Korean Journal of Internal Medicine Vol. 27, No. 1, march 2012
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for the prevention of renal dysfunction in patients 
with cirrhosis and ascites
To date, two different situations that may further impair 
circulatory function in cirrhotic patients with ascites have 
been identified: large-volume paracentesis and spontane-
ous bacterial peritonitis (SBP).
Large-volume paracentesis
The removal of large amounts of ascitic fluid is char-
acterized by early favorable hemodynamic effects, with 
suppression of vasoconstrictor and anti-natriuretic factors 
and increased plasma natriuretic peptide levels. However, 
this is followed by a second phase characterized by marked 
activation of vasoconstrictor and anti-natriuretic factors 
in the absence of changes in plasma volume, consistent 
with the impairment of effective arterial blood volume 
[20]. This paracentesis-induced circulatory dysfunction 
(PCD) occurs in most patients treated with large taps (> 5 
L), is not spontaneously reversible, and is associated with 
the impairment of renal function and decreased survival 
[11,21,22].
The prevention of PCD is the most controversial indica-
tion for albumin use, but the most important quantita-
tively. In the single randomized, controlled trial that com-
pared paracentesis plus albumin infusion (10 g/L of ascitic 
fluid removed) with paracentesis alone, the incidence of 
circulatory dysfunction was significantly decreased in the 
paracentesis plus albumin group (16%) compared with the 
paracentesis-only group (30%) [21]. Other plasma expand-
ers (e.g., dextran 70) were compared with albumin, and 
albumin was more effective only when > 5 L paracentesis 
was performed [22]. A single relatively large-volume para-
centesis (< 5 L) without albumin replacement was shown 
to have no deleterious consequence or adverse disturbance 
in systemic or renal hemodynamics [23]. As severely criti-
cally ill cirrhotic patients usually stay > 1 day in hospital, 
repeated small-volume paracentesis (< 5 L) will lessen the 
need for albumin infusion. In addition, no study to date 
has demonstrated a significant advantage of total paracen-
tesis compared with repeated smaller-volume paracentesis 
[19].
The American Association for the Study of Liver Disease 
(AASLD) recommended that albumin infusion should be 
given at a dose of 6-8 g/L ascites fluid removed for para-
centesis volumes > 5-6 L. Fifty percent should be given in 
the first hour (maximum 170 mL/hr) and the remainder in 
the next 6 hours [24]. The uses of albumin substitute flu-
ids, such as hydroxyethyl starch (HES), which can prevent 
circulatory failure after paracentesis remains controversial 
[2].
Spontaneous bacterial peritonitis
Patients with SBP risk systemic hemodynamic param-
eter deterioration, with further arterial and splanchnic 
vasodilatation. These patients are thus at high risk of 
developing renal insufficiency [25]. In a study of the ef-
fect of albumin infusion on renal function and survival in 
patients with SBP, 126 patients were randomly allocated 
to receive either cefotaxime alone or cefotaxime plus albu-
min infusions [26]. Albumin was given at a dose of 1.5 g/
kg body weight within 6 hours of SBP diagnosis, followed 
by a further infusion of 1 g/kg body weight on day 3. This 
strategy resulted in a large albumin infusion, for example, 
105 g on day 1 and 70 g on day 3 in a 70-kg patient. Pa-
tients who were given cefotaxime plus albumin infusions 
showed no increase in plasma renin activity, a decreased 
incidence of renal failure, and a decreased mortality rate 
(from 29% to 10%) compared with patients who were given 
cefotaxime alone. Criticisms of this study were the inclu-
sion of more sick control patients than those who received 
albumin with cefotaxime. Secondly, a central venous pres-
sure line was inserted only in patients with signs of hy-
povolemia. Thirdly, no comparison was made with other, 
less expensive, plasma volume expanders. These results 
suggest that the benefits of albumin infusion apply only to 
a subset of patients with more advanced liver disease. The 
amount of albumin used in this study was also high, mak-
ing this strategic therapy costly and impractical [19]. To 
address these criticisms, the authors of the original study 
compared infusions of albumin with infusions of HES for 
the prevention of renal failure in patients with SBP [27]. 
The findings supported the superiority of albumin in pre-
venting the development of renal failure in patients with 
SBP. Another study comparing albumin, crystalloid fluid, 
and artificial colloid corroborated this finding [28]. Al-
though albumin has a significant role in patients with SBP 
and severely disturbed liver and renal functions, its use 
continues to be debated because of the relatively high dose 
and cost [19,24]. Nevertheless, the development of renal 
failure in cirrhotic patients with SBP carries a high risk of 
morbidity and mortality, so the use of albumin infusion 
as an adjunctive therapy in the treatment of patients with Lee js. Albumin for liver disease    17
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SBP will continue until further trials are completed.
for the management of renal dysfunction in 
patients with cirrhosis and ascites
The administration of albumin to patients with cirrho-
sis and ascites causes an increase in total blood volume, 
followed by a moderate reduction, but not normalization, 
of the activity of vasoconstrictor and anti-natriuretic sys-
tems. These circulatory changes are associated with favor-
able effects on renal function. However, these renal effects 
are modest and limited only to patients with normal or 
slightly impaired renal function, whereas patients with 
severe renal dysfunction show no beneficial response [29-
32]. Albumin infusion alone fails to consistently improve 
circulatory and renal functions because albumin cannot 
increase effective arterial blood volume efficiently due to 
the extreme splanchnic vasodilatation present in these cir-
rhotic patients [1].
Hepatorenal syndrome (HRS) is characterized by very 
low arterial pressure and total systemic vascular resis-
tance, marked over-activity of vasoconstrictor factors, and 
marked arterial vasoconstriction in the kidney and other 
vascular territories (muscle, skin, and brain) [33]. For 
many years, HRS was considered a terminal irreversible 
event in patients with decompensated cirrhosis. However, 
it was demonstrated that patients with type 1 HRS may be 
effectively treated with a combination of vasoconstrictor 
and plasma volume expansion [34]. The use of albumin 
appears to increase the efficacy of vasoconstrictor drugs. 
Two studies have shown that the treatment of cirrhotic 
patients with HRS for several days or weeks with a combi-
nation of vasoconstrictors and plasma volume expansion 
with albumin results in a marked improvement in circula-
tory and renal functions in most cases, with normalization 
of plasma levels of vasoconstrictor factors and serum cre-
atinine [35,36]. However, the need for a plasma expander 
agent as a co-therapy remains unclear. The administra-
tion of vasoconstrictors with albumin has been shown to 
reverse type 1 HRS and normalize renal function in 60-
70% of treated patients. However, these studies included 
only small numbers of patients, some of whom were not 
randomized, and the impact on long-term (> 1 month) 
survival has not been shown. Available data on the treat-
ment of type 2 HRS are much scarcer than for type 1 HRS 
[19]. Whether albumin is required to achieve the beneficial 
effect of vasoconstrictor therapy in HRS is not known. 
However, albumin likely improves the therapeutic efficacy 
of vasoconstrictors, as the improvement in circulatory 
and renal functions is more marked in patients treated 
with terlipressin and albumin than that in patients treated 
with terlipressin alone. Given that albumin has volume-
expanding, ligand-binding, and antioxidant properties, it 
seems prudent to use albumin infusions in the treatment 
of HRS unless there is evidence that albumin actually does 
some harm. Currently, the AASLD recommends that albu-
min infusion plus administration of vasoactive drugs such 
as octreotide and midodrine should be considered in the 
treatment of type 1 HRS (level II-1).
Molecular adsorbent recirculating system
The recent development of the molecular absorbent 
recirculating system (MARS), an albumin dialysis that 
removes albumin-bound and water-soluble substances in 
patients with acute and chronic liver failure, is a clinical 
application for albumin, based on its capacity to remove 
water-insoluble substances [37]. The MARS system has 
been shown to be very effective in the treatment of hepatic 
encephalopathy [38] and intractable pruritus. Further-
more, it markedly improves circulatory and renal func-
tions in patients with cirrhosis and ascites [39,40]. Several 
randomized controlled trials have been performed to as-
sess the use of MARS in patients with acute and chronic 
liver failure. Despite encouraging results, the role of MARS 
in the management of patients with end-stage cirrhosis 
remains unsettled because all reports published to date 
were based on small studies. Furthermore, MARS is an 
expensive treatment that requires skilled personnel. The 
use of MARS in patients with acute or chronic liver failure 
showed an improvement in hepatic encephalopathy, but 
not in systemic hemodynamic parameters or renal func-
tion [41]. Future studies will need to define the indications 
for MARS treatment, patient selection, and predictors for 
response.
Other complications of cirrhosis
Hyponatremia is common complication in patients with 
advanced cirrhosis. Hyponatremia is usually the result of 
vasopressin overactivity in response to a reduction in the 
effective arterial blood volume. As albumin is capable of 
refilling the effective arterial blood volume, albumin infu-
sions have been used in the treatment of this complication 
[42]. To date, however, no study has compared the efficacy 18    The Korean Journal of Internal Medicine Vol. 27, No. 1, march 2012
http://dx.doi.org/10.3904/kjim.2012.27.1.13 http://www.kjim.or.kr
of albumin infusions with those of other volume expand-
ers in the treatment of hyponatremia. Diuretic-induced 
electrolyte abnormalities can also lead to the development 
of hepatic encephalopathy in patients with cirrhosis. In a 
study conducted in cirrhotic patients with diuretic-induced 
hepatic encephalopathy, the infusion of albumin was com-
parably effective to the infusion of a colloid solution. These 
infusions caused similar reductions in plasma ammonia 
concentrations and increases in urinary ammonia excre-
tion. The improvement of hepatic encephalopathy grade, 
although initially observed in both groups of patients, was 
only sustained at 72 hours in the group who received albu-
min infusions [43].
CONCLUSION
The use of albumin in patients with liver diseases has 
followed a seesaw evolution. Initially, it was widely used to 
increase serum albumin concentration and to treat ascites. 
At this moment, with several randomized trials and pilot 
studies indicating that albumin is extremely effective in 
the prevention and treatment of circulatory dysfunction 
and HRS in patients with cirrhosis, this molecule is again 
becoming an essential treatment in clinical hepatology. 
Finally, the MARS system, which has opened the hemo-
dialysis world to patients with acute and chronic liver 
failure, will increase our knowledge of the mechanisms of 
action of albumin and will probably expand the therapeu-
tic indications of this molecule. Without doubt, albumin 
will be an exciting topic for research in the near future, as 
it was many years ago. Future efforts should concentrate 
on establishing when, how much, and for what indications 
albumin should be used.
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